[Effect of SL 25 on radiogenic xerostomia in the radiotherapy of tumors in the region of neck and face (author's transl)].
The radiogenic xerostomia often poses problems to the radiotherapeutist because this symptom can become so severe that treatment has to be interrupted or in some cases even stopped. The therapeutic success can become uncertain because of such deviations from the irradiation scheme. Because of promising observations reported in literature, we have examined the stimulating effect on the salivation produced by the test preparation SL 25 from Kali-Chemie Pharma GmbH in Hannover. A double blindfold test was made. Only three out of fourteen patients (22%) in the active substance group declared to feel a relief of the xerostomia, whereas in the control group five out of twenty patients (25%) felt this relief.
D000781:Anethole Trithione / Q000627:therapeutic use*; D000840:Anisoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005153:Facial Neoplasms / Q000532:radiotherapy*; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D011832:Radiation Injuries / Q000188:drug therapy*; D011879:Radiotherapy Dosage; D014987:Xerostomia / Q000188:drug therapy* / Q000209:etiology
D000840:Anisoles; D000781:Anethole Trithione
Die Wirkung von SL 25 auf die radiogene Xerostomie bei der Strahlentherapie von Tumoren im Hals- und Gesichtsbereich.